Antisense & RNAi Therapeutics Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Antisense & RNAi 
Therapeutics Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t l ed  "Ant isense  & RNAi  
Therapeut ics  Market :  G loba l  Industry  Trends,  Share ,  S ize ,  Growth ,  
Oppor tuni ty  and Forecas t  2024 -2032 ,"  the  g loba l  an t isense  &  RNA i  
the rapeu t ics  marke t  s ize  reached  US$ 1 .7  B i l l ion  in  2023 .
Report Ant isense  the rapeu t ics  invo lve  the  use  o f  shor t ,  syn the t ic  nuc leo t ide  
sequences  tha t  a re  des igned  to  b ind  comp lementa ry  messenger  RNA (mRNA) 
Highlight and molecu les  and  inh ib i t  the  t rans la t ion  o f  spec i f i c  p ro te ins .  On  the  o ther  hand ,  RNAi  the rapeu t ics  u t i l i ze  sma l l  in te r fe r ing  RNA (s iRNA)  mo lecu les  to  s i lence  
the  express ion  o f  d isease-caus ing  genes  a t  the  pos t - t ranscr ip t iona l  leve l .  
Description As they  o f fe r  enhanced  t rea tment  fo r  gene t ic  d i so rders ,  v i ra l  i n fec t ions ,  and  
ce r ta in  t ypes  o f  cancers ,  the  demand fo r  an t isense  and  RNA i  the rapeu t ics  is  
inc reas ing  ac ross  the  g lobe .
Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/an t isense- rna i - the rapeu t ics -marke t / reques tsamp le
Report Description
Global  Ant isense  &  RNAi  Therapeut ics  Market  Trends :
At  p resen t ,  the  r i s ing  demand fo r  d isease  management  to  regu la te  gene  express ion  i s  suppor t i ng  the  g rowth  o f  
the  marke t .  Bes ides  th is ,  t he  inc reas ing  adop t ion  o f  an t isense  and  RNAi  the rap ies ,  as  they  o f fe r  h igh ly  spec i f i c  
and  persona l ized  approaches  tha t  ca te r  t o  t rea tments  to  spec i f i c  gene t ic  p ro f i l es  o f  ind iv idua ls ,  i s  s t reng then ing  
the  g rowth  o f  the  marke t .  
In  l ine  w i th  th is ,  the  g rowing  demand fo r  p rec is ion  med ic ine  among ind iv idua ls  i s  pos i t i ve l y  i n f luenc ing  the  
marke t .  Apa r t  f rom th is ,  t he  inc reas ing  p reva lence  o f  neurodegene ra t ive  d iseases ,  such  as  A lzhe imer ' s  and  
Park inson 's  d isease ,  ac ross  the  g lobe  i s  o f fe r ing  luc ra t ive  g rowth  oppo r tun i t i es  to  i ndust ry  i nves to rs .  I n  add i t i on ,  
the  r i s ing  demand  fo r  t he rap ies  tha t  reduce  d isease  p rog ress ion  is  bo ls te r ing  the  g rowth  o f  the  marke t .
Look ing  forward ,  the  market  va lue  is  pro jected to  reach US$ 3 .2  B i l l ion  by  2032 ,  expanding a t  a  CAGR of  
7 .25% dur ing  2024-2032 .
V iew Repor t  TOC,  F igures  and  Tables :  h t tps: / /www. imarcgroup.com/ant isense-rna i - therapeut ics-market
Breakup by Technology:
• RNA Interference
o s iRNA
o miRNA
• Ant isense RNA
 
Breakup by Route of Administration:
Report • Intravenous Route
Segmentation • Subcutaneous Route
• Intrathecal  Route
• Pulmonary Del ivery
• Intraper i toneal  In ject ion
• Others
Breakup by Application:
• Oncology
• Cardiovascular Diseases (CVDs)
• Respiratory Disorders
• Renal Diseases
• Neurodegenerat ive Disorders
• Genetic Disorders
• Infect ious Diseases
Report • Others
Segmentation
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Alnylam Pharmaceuticals Inc. ,
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals Inc.
• Benitec Biopharma Ltd.
Competitive 
• Bio-Path Holdings Inc.
Landscape • Dicerna Pharmaceuticals Inc.  (Novo Nordisk 
A/S)
with Key 
• Ionis Pharmaceuticals Inc.
Players • OliX Pharmaceuticals Inc.
• Phio Pharmaceuticals Corp.
• Sarepta Therapeutics Inc.
• Silence Therapeutics
• Sirnaomics Inc.
How big is the global antisense & RNAi therapeutics 
market?
What is the expected growth rate of the global 
antisense & RNAi therapeutics market during 2024-
2032?
What are the key factors driving the global antisense & 
Key RNAi therapeutics market?
Questions What has been the impact of COVID-19 on the global 
antisense & RNAi therapeutics market?
Answered in 
What is the breakup of the global antisense & RNAi 
therapeutics market based on the technology?
the Report
What is the breakup of the global antisense & RNAi 
therapeutics market based on the route of 
administration?
What are the key regions in the global antisense & RNAi 
therapeutics market?
Who are the key players/companies in the global 
antisense & RNAi therapeutics market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  A n t i s e n s e  &  R N A i  T h e r a p e u t i c s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T e c h n o l o g y
    6 . 1     R N A  I n t e r f e r e n c e
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  K e y  S e g m e n t s
           6 . 1 . 2 . 1  s i R N A
           6 . 1 . 2 . 2  m i R N A
        6 . 1 . 3  M a r k e t  F o r e c a s t
    6 . 2     A n t i s e n s e  R N A
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
       
7    M a r k e t  B r e a k u p  b y  R o u t e  o f  A d m i n i s t r a t i o n
    7 . 1     I n t r a v e n o u s  R o u t e
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     S u b c u t a n e o u s  R o u t e
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     I n t r a t h e c a l  R o u t e
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
Table of     7 . 4     P u l m o n a r y  D e l i v e r y        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     I n t r a p e r i t o n e a l  I n j e c t i o n
Contents         7 . 5 . 1  M a r k e t  T r e n d s        7 . 5 . 2  M a r k e t  F o r e c a s t
    7 . 6     O t h e r s
        7 . 6 . 1  M a r k e t  T r e n d s
        7 . 6 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  A p p l i c a t i o n
    8 . 1     O n c o l o g y
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     C a r d i o v a s c u l a r  D i s e a s e s  ( C V D s )
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     R e s p i r a t o r y  D i s o r d e r s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / a n t i s en s e - rn a i - t h e r a p e u t i c s - m a r ke
t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]